- Reduced Angiogenesis: Decrease in VEGF secretion.
---
4. Pharmacokinetic Profile
Parameter Typical Value (Human)
Absorption Oral bioavailability ≈ 35–45 % (moderate). Peak plasma concentration reached within 1–2 h post‑dose.
Distribution Volume of distribution ~5 L/kg; extensive protein binding (~85 %) predominantly to albumin and α₁‑acid glycoprotein. Crosses placental barrier efficiently (fetal/maternal ratio ≈ 0.8). Low penetration into cerebrospinal fluid (~10 % of plasma).
Metabolism Predominantly hepatic via CYP3A4 (≈70 %) and CYP2C9 (≈20 %). Minor contributions from UGT1A1 glucuronidation. Metabolites largely inactive; no major reactive intermediates.
Excretion Renal excretion of unchanged drug (~25 % of dose) through glomerular filtration and active tubular secretion (via OATs). Hepatic biliary excretion contributes ~30 %. Urinary pH influences renal clearance (acidic urine increases reabsorption).
Half‑life Apparent elimination half‑life ≈ 4–6 h in healthy adults. Slightly prolonged in mild hepatic impairment; negligible change in moderate to severe kidney disease due to compensatory biliary excretion.
Pharmacokinetic Profile Summary
Absorption: Rapid, high oral bioavailability (~80–90 %).
Distribution: Moderate protein binding (~30 %), extensive plasma exposure.
Metabolism: Primarily CYP3A4 oxidation (short‑lived metabolites) with minor glucuronidation via UGT1A9/UGT2B7.
Excretion: Dual pathway—biliary elimination of unchanged drug and metabolites, plus renal excretion (~30 % as parent).
Drug–drug interaction potential: Significant CYP3A4-mediated interactions (strong inhibitors or inducers alter exposure). UGT inhibitors/inducers have less pronounced effect.
Key Take‑away
Compound 1 is mainly cleared by hepatic metabolism through CYP3A4, with a modest role for glucuronidation. The unchanged drug and its metabolites are excreted via bile (largely as glucuronides) and to a lesser extent by the kidneys. Therefore, any co‑administered agent that strongly inhibits or induces CYP3A4—or, to a lesser degree, UGT1A1—will substantially modify the pharmacokinetics of this compound.
Higit sa 30 milyong kanta na angkop sa bawat mood at okasyon
Gumawa ng sarili mong playlist
Magbahagi ng musika sa mga kaibigan at pamilya
I-save ang iyong mga paborito
Tanggalin ang iyong track
Sigurado ka bang gusto mong tanggalin ang track na ito?
Tanggalin ang komento
Sigurado ka bang gusto mong tanggalin ang komentong ito?
Tanggalin ang komento
Sigurado ka bang gusto mong tanggalin ang komentong ito?
Tanggalin ang iyong post
Sigurado ka bang gusto mong tanggalin ang post na ito?
Matagumpay na naibahagi ang kanta sa iyong timeline.
Kinakailangan ang Pagbili
Upang magpatuloy sa pakikinig sa track na ito, kailangan mong bilhin ang kanta.
Track na pinaghihigpitan sa edad
Ang track na ito ay pinaghihigpitan sa edad para sa mga manonood na wala pang 18 taong gulang, Gumawa ng account o mag-login para kumpirmahin ang iyong edad.
Gumawa ng DMCA take down notice
Ang ulat ng komento ay matagumpay na natanggal.
Mag-ulat ng komento.
Ang ulat ng komento ay matagumpay na natanggal.
Mag-ulat ng komento.
Matagumpay na natanggal ang ulat ng track.
Track ng ulat.
Matagumpay na natanggal ang ulat ng track.
Suriin ang track.
Nag-expire na ang Session
Ang iyong Session ay nag-expire na, mangyaring mag-login muli.
Isang email ng kumpirmasyon ang naipadala.
Request a Refund
Add New Address
Delete your address
Are you sure you want to delete this address?
Payment Alert
You are about to purchase the items, do you want to proceed?
